Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 1.00 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8406210 | 1.00 | BRD4 (1.00) | BRD4SRD5A1HPGDTSHRPDE4A | |
| SCHEMBL15203831 | 1.00 | BRD4 (1.00) | BRD4SRD5A1HPGDTSHRPDE4A | |
| SCHEMBL18590522 | 0.83 | BRD4 (0.72) | BRD4SRD5A1PDE4APDE4BPDE4C | |
| SCHEMBL18590524 | 0.83 | BRD4 (0.72) | BRD4SRD5A1PDE4APDE4BPDE4C | |
| SCHEMBL18590523 | 0.83 | BRD4 (0.72) | BRD4SRD5A1PDE4APDE4BPDE4C | |
| SCHEMBL30912528 | 0.81 | BRD4 (0.70) | BRD4SRD5A1PDE4APDE4BPDE4C | |
| SCHEMBL30912553 | 0.81 | BRD4 (0.70) | BRD4SRD5A1PDE4APDE4BPDE4C | |
| SCHEMBL10756940 | 0.81 | BRD4 (0.70) | BRD4SRD5A1PDE4APDE4BPDE4C | |
| SCHEMBL12719792 | 0.81 | BRD4 (0.69) | BRD4SRD5A1HPGDTSHRMEN1 | |
| SCHEMBL16591470 | 0.81 | SRD5A1 (1.00) | BRD4SRD5A1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784167-B2 | TREATING OSTEOPOROSIS, OSTEOPENIA, OVARIAN CANCER, BREAST CANCER, ENDOMETRIAL CANCER, ENDOMETRIOSIS, PROSTATE CANCER, ACNE, ANDROGEN-DEPENDENT HAIR LOSS, NON-INSULIN-DEPENDENT DIABETES MELLITUS, OR HYPERCHOLESTEROLEMIA. | BAYER PHARMACEUTICALS CORPORATION | 2004-08-31 | — | — | US | claimed |
| US-12590078-B2 | — | — | 2026-03-31 | — | — | US | disclosed |
| WO-2024102348-A1 | SEALANT REMOVER | ILLINOIS TOOL WORKS INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2023107557-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20220213059-A1 | INHIBITING USP19 | Valo Health, LLC | 2022-07-07 | — | — | US | disclosed |
| EP-2686321-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2016-11-16 | — | — | EP | disclosed |
| US-8987268-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140323519-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323519-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| CN-1113872-C | Tricyclicbenzo [3] isoindole and benzo (h) isoquinoline | HOFFMANN LA ROCHE (CH) | 2003-07-09 | — | — | CN | disclosed |
| US-20030087952-A1 | 17-Beta-hydroxysteroid dehydrogenase-II inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2003-05-08 | — | — | US | disclosed |
| WO-2002026706-A2 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE-II INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2002-04-04 | — | — | WO | disclosed |
| US-6310208-B1 | Serotonin receptor binding benzo[e]isoindoles and benzo[h]isoquinolines | HOFFMANN-LA ROCHE INC. | 2001-10-30 | — | — | US | disclosed |
| CN-1243510-A | Tricyclicbenzo [3] isoindole and benzo (h) isoquinoline | HOFFMANN LA ROCHE (CH) | 2000-02-02 | — | — | CN | disclosed |
| EP-0958285-A1 | TRICYCLIC BENZO[e]ISOINDOLES AND BENZO[h]ISOQUINOLINES | F.HOFFMANN-LA ROCHE AG (CH) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998030546-A1 | TRICYCLIC BENZO[e]ISOINDOLES AND BENZO[h]ISOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-16 | — | — | WO | disclosed |
| US-4699918-A | ANTICOAGULANTS, ANTIARRHYTHMIA AGENTS | LABORATOIRES JACQUES LOGEAIS (FR) | 1987-10-13 | — | — | US | disclosed |
| EP-0222163-A1 | Process for the manufacture of gamma-butyrolactames | BAYER AG (DE) | 1987-05-20 | — | — | EP | disclosed |
| US-4556674-A | ANTICOAGULANTS, ANTIARRHYTHMIA AGENTS | LABORATOIRES JACQUES LOGEAIS (FR) | 1985-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213059-A1 | INHIBITING USP19 | USP19, UBQLN2, UBQLN1 | BRD4 2829/4885SRD5A1 2562/4885HPGD 1996/4885 |
| US-12590078-B2 | — | ADRM1, USP19, USP1 | BRD4 2266/4885SRD5A1 675/4885HPGD 4102/4885 |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | BRD4 528/4885SRD5A1 2537/4885HPGD 2140/4885 |
| US-20140323519-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | BRAF, RAF1, NRAS | BRD4 44/4885SRD5A1 2530/4885HPGD 961/4885 |
| US-20030087952-A1 | 17-Beta-hydroxysteroid dehydrogenase-II inhibitors | HSD3B1, HSD3B2, HSD17B1 | BRD4 3610/4885SRD5A1 8/4885HPGD 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.